Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on developing therapies for retinal diseases and eye conditions, has announced inducement awards for its newly appointed Director of IT Cybersecurity, Russell Isaacs. The awards, granted under Ocular's 2019 Inducement Stock Incentive Plan, include:
1. Non-statutory stock options: 14,000 shares at market price, vesting over four years
2. Restricted stock unit awards: 4,666 shares, vesting over three years
These equity awards are designed to incentivize Mr. Isaacs' employment with Ocular and are subject to his continued service with the company. The grants comply with Nasdaq Listing Rule 5635(c)(4) and were effective as of September 9, 2024.
Ocular Therapeutix (NASDAQ: OCUL), una compagnia biofarmaceutica focalizzata nello sviluppo di terapie per malattie retiniche e condizioni oculari, ha annunciato premi di incentivazione per il suo nuovo Direttore della Cybersecurity IT, Russell Isaacs. I premi, concessi nell'ambito del Piano di Incentivazione Azionaria del 2019 di Ocular, includono:
1. Opzioni azionarie non statutarie: 14.000 azioni al prezzo di mercato, con maturazione su un periodo di quattro anni
2. Premi in azioni soggette a restrizioni: 4.666 azioni, con maturazione su un periodo di tre anni
Questi premi azionari sono progettati per incentivare l'impiego del signor Isaacs presso Ocular e sono soggetti al suo continuo servizio con l'azienda. Le concessioni sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) ed erano efficaci a partire dal 9 settembre 2024.
Ocular Therapeutix (NASDAQ: OCUL), una compañía biofarmacéutica centrada en el desarrollo de terapias para enfermedades retinianas y condiciones oculares, ha anunciado premios de inducción para su recién nombrado Director de Ciberseguridad IT, Russell Isaacs. Los premios, otorgados bajo el Plan de Incentivos Accionarios de Inducción 2019 de Ocular, incluyen:
1. Opciones de acciones no estatutarias: 14,000 acciones al precio de mercado, que se adquirirán durante cuatro años
2. Premios de unidades de acciones restringidas: 4,666 acciones, que se adquirirán durante tres años
Estos premios de capital están diseñados para incentivar el empleo del Sr. Isaacs en Ocular y están sujetos a su servicio continuo con la empresa. Las concesiones cumplen con la Regla de Cotización del Nasdaq 5635(c)(4) y entraron en vigor el 9 de septiembre de 2024.
Ocular Therapeutix (NASDAQ: OCUL)은 망막 질환과 안과적 상태에 대한 치료제를 개발하는 데 초점을 맞춘 생명공학 회사로, 새로 임명된 IT 사이버 보안 이사 러셀 아이작스를 위한 유인 보상을 발표했습니다. 이 보상은 Ocular의 2019 인센티브 주식 계획에 따라 부여되며, 다음을 포함합니다:
1. 비법정 주식 옵션: 14,000 주, 시장 가격으로, 4년에 걸쳐 분할 지급
2. 제한된 주식 단위 보상: 4,666 주, 3년에 걸쳐 분할 지급
이러한 주식 보상은 아이작스 씨의 Ocular 고용을 장려하기 위해 설계되었으며, 회사에서의 지속적인 근무에 따라 달라집니다. 이 보상은 나스닥 상장 규칙 5635(c)(4)에 부합하며, 2024년 9월 9일부터 효력이 발생했습니다.
Ocular Therapeutix (NASDAQ: OCUL), une entreprise biopharmaceutique axée sur le développement de thérapies pour les maladies rétiniennes et les conditions oculaires, a annoncé des récompenses d'incitation pour son nouveau directeur de la cybersécurité IT, Russell Isaacs. Les récompenses, accordées dans le cadre du Plan d'Incitation en Actions 2019 d'Ocular, comprennent :
1. Options d'action non statutaires : 14 000 actions au prix du marché, avec une acquisition sur quatre ans
2. Attributions d'unités d'actions restreintes : 4 666 actions, avec une acquisition sur trois ans
Ces récompenses en actions sont conçues pour inciter l'emploi de M. Isaacs chez Ocular et sont soumises à son service continu au sein de l'entreprise. Les attributions sont conformes à la règle de cotation Nasdaq 5635(c)(4) et ont été effectives à partir du 9 septembre 2024.
Ocular Therapeutix (NASDAQ: OCUL), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für Netzhauterkrankungen und Augenkrankheiten konzentriert, hat Anreizpreise für seinen neu ernannten Direktor für IT-Cybersicherheit, Russell Isaacs, bekannt gegeben. Die Preise, die im Rahmen des Anreiz-Aktienplans 2019 von Ocular gewährt werden, umfassen:
1. Nicht-statutäre Aktienoptionen: 14.000 Aktien zum Marktpreis, mit einer Vesting-Dauer von vier Jahren
2. Auszeichnungen für eingeschränkte Aktieneinheiten: 4.666 Aktien, mit einer Vesting-Dauer von drei Jahren
Diese Eigenkapitalpreise sind darauf ausgelegt, Herrn Isaacs' Anstellung bei Ocular zu fördern und sind an seine fortdauernde Tätigkeit im Unternehmen gebunden. Die Gewährungen entsprechen der Nasdaq-Listingregel 5635(c)(4) und wurden am 9. September 2024 wirksam.
- Appointment of a new Director of IT Cybersecurity, potentially strengthening the company's cybersecurity measures
- Implementation of an incentive plan to attract and retain key talent
- Potential dilution of existing shareholders due to the issuance of new stock options and restricted stock units
BEDFORD, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to its newly appointed Director, IT Cybersecurity, Russell Isaacs. The awards were made as inducements material to Mr. Isaacs’ acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Mr. Isaacs’ inducement equity awards were granted effective as of September 9, 2024. Mr. Isaacs’ inducement equity awards consist of (i) non-statutory stock options to purchase up to 14,000 shares of Ocular’s common stock at a per share exercise price equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant and (ii) restricted stock unit awards representing the right to receive 4,666 shares of Ocular’s common stock. The stock option has a ten-year term and is scheduled to vest over four years, with
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What inducement awards did Ocular Therapeutix (OCUL) grant to Russell Isaacs?
When will the stock options granted by Ocular Therapeutix (OCUL) to Russell Isaacs vest?
What is the vesting schedule for the restricted stock units granted by Ocular Therapeutix (OCUL)?
Under what plan were the inducement awards granted by Ocular Therapeutix (OCUL)?
